Latest News
Trevi Therapeutics, Inc.
- Trevi Therapeutics presents CHEST data: BMO rates Trevi Therapeutics stock Outperform
- Trevi Therapeutics (TRVI) Following GSK Exit Is Its Chronic Cough Valuation Back In Focus
- Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
- Trevi Therapeutics Q2 2026 Earnings Call Transcript
- BMO reiterates Trevi Therapeutics stock rating after rival study fails
- Trevi Therapeutics (TRVI) Edges Lower to $14.18, Holding Mid-Range Between Key Levels - Intraday Trade Ideas
- Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update
Headlines from the last 30 days, linking to the original publishers. See all market news →